<DOC>
	<DOCNO>NCT02085252</DOCNO>
	<brief_summary>The purpose study assess two treatment strategy ( leuprorelin treatment active surveillance without androgen deprivation ) indolent prostate cancer compare therapeutic benefit management patient low-risk , localized prostate cancer .</brief_summary>
	<brief_title>A Study Effect Enantone LP 11.25 mg ( Leuprorelin ) Histological Progression Indolent Prostate Cancer</brief_title>
	<detailed_description>The drug test study call leuprorelin . Leuprorelin test treat people prostate cancer . Study assessment include adverse event , prostatic-specific antigen ( PSA ) level , prostate biopsy . The study enroll approximately 120 patient . Participants randomly assign ( chance , like flip coin ) treatment group receive leuprorelin 11.25 mg ( one injection ) untreated observation group . Patients leuprorelin group also receive bicalutamide 50 mg , non-steroidal antiandrogen , daily 15 day prevent flare-up . This multi-center trial conduct France . The overall time participate study 12 month . After screen visit , participant make 6 visit clinic .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>1 . Is outpatient 50 80 year old . 2 . Has read , understood , sign date informed consent . 3 . Has indolent prostate cancer define : Clinical Stage T1c T2a . Biopsy core least 12 reveal presence positive core absence core tumor length &gt; 3 mm . Absence Grade 4 cell ( Gleason &lt; 7 ) . Prostate specific antigen ( PSA ) level &lt; 10 ng/ml . 4 . Has life expectancy &gt; 5 year . 5 . Has accept principle active surveillance . 6 . Is willing participate study minimum fifteen month . 1 . Has prior androgen deprivation include 5alpha reductase inhibitor ( finasteride dutasteride ) within last 6 month . 2 . Has psychological failure relate prostate cancer therapy . 3 . Has active disorder likely affect conduct study patient 's prognosis study . 4 . Has mental condition reason may hinder understand strict application protocol . 5 . Is judicial protection . 6 . Is unlikely attend control visit . 7 . Is currently enrol investigational study participate another investigational study within last 3 month . 8 . Has allergy hypersensitivity component leuprorelin ( Enantone LP ) 11.25 mg CasodexÂ® 50 mg. 9 . Has medical history severely impaired hepatic function link bicalutamide pathological cause . 10 . Has testosterone level &lt; 0.5 ng/ml .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>